These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28418843)

  • 21. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
    Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors.
    Colonna SV; Higgins AK; Alvarez J; Saville BR; Lawrence J; Abramson VG
    Clin Breast Cancer; 2016 Jun; 16(3):223-31. PubMed ID: 26683741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.
    Wu Y; Sarkissyan M; Elshimali Y; Vadgama JV
    PLoS One; 2013; 8(10):e78259. PubMed ID: 24167614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
    Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
    Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
    Sicchieri RD; da Silveira WA; Mandarano LR; de Oliveira TM; Carrara HH; Muglia VF; de Andrade JM; Tiezzi DG
    Tumour Biol; 2015 Dec; 36(12):9233-43. PubMed ID: 26091795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
    Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
    Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer.
    Tian J; Hachim MY; Hachim IY; Dai M; Lo C; Raffa FA; Ali S; Lebrun JJ
    Sci Rep; 2017 Jan; 7():40258. PubMed ID: 28054666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
    Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
    Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
    Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
    Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
    Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
    Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer.
    O'Hurley G; Daly E; O'Grady A; Cummins R; Quinn C; Flanagan L; Pierce A; Fan Y; Lynn MA; Rafferty M; Fitzgerald D; Pontén F; Duffy MJ; Jirström K; Kay EW; Gallagher WM
    Histopathology; 2014 Apr; 64(5):660-70. PubMed ID: 24138071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells.
    Jiang M; Zhuang H; Xia R; Gan L; Wu Y; Ma J; Sun Y; Zhuang Z
    Oncotarget; 2017 Nov; 8(54):92106-92118. PubMed ID: 29190901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.
    Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH
    Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
    Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.